(Q46597773)

23 December 2017

title

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements (English)

1 reference

23 December 2017

author name string

Shivanni Kummar

1 reference

23 December 2017

John Wright

1 reference

23 December 2017

Susan Holbeck

1 reference

23 December 2017

Myrtle Davis Millin

1 reference

23 December 2017

Joseph Tomaszewski

1 reference

23 December 2017

James Zweibel

1 reference

23 December 2017

Jerry Collins

1 reference

23 December 2017

Helen X. Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031001

16 August 2024

James H. Doroshow

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21031001

16 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21031001

16 August 2024

publication date

29 October 2010

1 reference

23 December 2017

full work available at URL

http://www.nature.com/articles/nrd3216.pdf

1 reference

https://api.crossref.org/works/10.1038/NRD3216

http://www.nature.com/articles/nrd3216

16 August 2024

1 reference

https://api.crossref.org/works/10.1038/NRD3216

Nature Reviews Drug Discovery

16 August 2024

published in

1 reference

23 December 2017

volume

1 reference

23 December 2017

issue

1 reference

23 December 2017

page(s)

843-856

1 reference

23 December 2017

Perspectives on the development of imatinib and the future of cancer research

cites work

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

31 March 2020

1 reference

Design and analysis issues in genome-wide somatic mutation studies of cancer

31 March 2020

1 reference

The use of drugs in combination for the treatment of cancer: rationale and results

31 March 2020

1 reference

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

31 March 2020

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

Targeted cancer therapeutics

31 March 2020

1 reference

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

31 March 2020

1 reference

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines

31 March 2020

1 reference

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

31 March 2020

1 reference

Pharmacodynamic biomarkers for molecular cancer therapeutics

31 March 2020

1 reference

Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient

31 March 2020

1 reference

Strategies for optimizing combinations of molecularly targeted anticancer agents

31 March 2020

1 reference

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

31 March 2020

1 reference

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

31 March 2020

1 reference

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

31 March 2020

1 reference

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

31 March 2020

1 reference

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway

31 March 2020

1 reference

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

31 March 2020

1 reference

Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer

31 March 2020

1 reference

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer

31 March 2020

1 reference

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

31 March 2020

1 reference

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

31 March 2020

1 reference

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

31 March 2020

1 reference

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

31 March 2020

1 reference

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

31 March 2020

1 reference

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

31 March 2020

1 reference

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

31 March 2020

1 reference

Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair

31 March 2020

1 reference

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

31 March 2020

1 reference

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

31 March 2020

1 reference

Inhibition of Vascular Endothelial Growth Factor Receptor-1/Wnt/{beta}-catenin Crosstalk Leads to Tumor Cell Death.

31 March 2020

1 reference

Vascular Endothelial Growth Factor Receptor-1 Is Synthetic Lethal to Aberrant {beta}-Catenin Activation in Colon Cancer

31 March 2020

1 reference

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

31 March 2020

1 reference

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

31 March 2020

1 reference

Combination chemical genetics

31 March 2020

1 reference

Multidimensional drug profiling by automated microscopy

31 March 2020

1 reference

Systematic discovery of multicomponent therapeutics

31 March 2020

1 reference

The NCI60 human tumour cell line anticancer drug screen

31 March 2020

1 reference

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells

31 March 2020

1 reference

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

31 March 2020

1 reference

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

31 March 2020

1 reference

Preclinical modeling of combination treatments: fantasy or requirement?

31 March 2020

1 reference

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

31 March 2020

1 reference

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

31 March 2020

1 reference

Designing phase 0 cancer clinical trials

31 March 2020

1 reference

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development

31 March 2020

1 reference

Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

31 March 2020

1 reference

Compressing drug development timelines in oncology using phase '0' trials.

31 March 2020

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

31 March 2020

1 reference

Pathway analysis tools and toxicogenomics reference databases for risk assessment

31 March 2020

1 reference

Predictive toxicogenomics in preclinical discovery

31 March 2020

1 reference

Is anticancer drug development heading in the right direction?

31 March 2020

1 reference

Targeted agents: the rules of combination

31 March 2020

1 reference

Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies

31 March 2020

1 reference

Sorafenib for metastatic renal cancer: the Princess Margaret experience

31 March 2020

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

31 March 2020

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

31 March 2020

1 reference

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

31 March 2020

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

Combination cancer therapy: Presidential address

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21031001

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

2593

E Frei III.

1972

1 reference

https://api.crossref.org/works/10.1038/NRD3216

16 August 2024

Identifiers

DOI

10.1038/NRD3216

1 reference

23 December 2017

1 reference

23 December 2017